The STK11/LKB1 is a tumor suppressor involved in metabolism and cell motility. In BRAF$^{V600E}$ melanoma, STK11 is inactivated by extracellular signal‒regulated kinase and RSK, preventing it from binding and activating adenosine monophosphate-activated protein kinase and promoting melanoma cell proliferation. Although STK11 mutations occur in 5‒10% of cutaneous melanoma, few functional studies have been performed. By knocking out STK11 with CRISPR/Cas9 in two human BRAF-mutant melanoma cell lines, we found that STK11 loss reduced the sensitivity to a BRAF inhibitor. More strikingly, STK11 loss led to an increased invasive phenotype in both three-dimensional spheroids and in vivo zebrafish xenograft models. STK11 overexpression consistently...
Somatic inactivation of the serine/threonine kinase gene STK11/LKB1/PAR-4 occurs in a variety of can...
Oncogenic mutations in BRAF are common in melanoma and drive constitutive activation of the MEK/ERK ...
Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon...
The STK11/LKB1 is a tumor suppressor involved in metabolism and cell motility. In BRAF$^{V600E}$ mel...
The serine/threonine kinase 11 (STK11/LKB1) is a tumor suppressor involved in metabolism and cell mo...
The serine/threonine kinase 11 (STK11/LKB1) is a tumor suppressor involved in metabolism and cell mo...
SummaryGermline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), whic...
Treatment of melanoma with a BRAF inhibitor (BRAFi) frequently initiates development of BRAFi resist...
Cyclin dependent kinase 11 (CDK11) is a protein kinase that regulates RNA transcription, pre-mRNA sp...
Germline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), which inclu...
Activating mutations in NRAS account for 20%–30% of melanoma, but despite decades of research and in...
Although advances in cytotoxic treatments have been obtained in several neoplasias, in metastatic me...
We generated cell lines resistant to BRAF inhibitors and show that the EGF receptor (EGFR)-SRC famil...
Melanoma is among the most heterogeneous and aggressive type of cancers. The BRAFV600E mutation, fou...
Copyright © 2013 Zdena Tuháčková et al. This is an open access article distributed under the Creativ...
Somatic inactivation of the serine/threonine kinase gene STK11/LKB1/PAR-4 occurs in a variety of can...
Oncogenic mutations in BRAF are common in melanoma and drive constitutive activation of the MEK/ERK ...
Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon...
The STK11/LKB1 is a tumor suppressor involved in metabolism and cell motility. In BRAF$^{V600E}$ mel...
The serine/threonine kinase 11 (STK11/LKB1) is a tumor suppressor involved in metabolism and cell mo...
The serine/threonine kinase 11 (STK11/LKB1) is a tumor suppressor involved in metabolism and cell mo...
SummaryGermline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), whic...
Treatment of melanoma with a BRAF inhibitor (BRAFi) frequently initiates development of BRAFi resist...
Cyclin dependent kinase 11 (CDK11) is a protein kinase that regulates RNA transcription, pre-mRNA sp...
Germline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), which inclu...
Activating mutations in NRAS account for 20%–30% of melanoma, but despite decades of research and in...
Although advances in cytotoxic treatments have been obtained in several neoplasias, in metastatic me...
We generated cell lines resistant to BRAF inhibitors and show that the EGF receptor (EGFR)-SRC famil...
Melanoma is among the most heterogeneous and aggressive type of cancers. The BRAFV600E mutation, fou...
Copyright © 2013 Zdena Tuháčková et al. This is an open access article distributed under the Creativ...
Somatic inactivation of the serine/threonine kinase gene STK11/LKB1/PAR-4 occurs in a variety of can...
Oncogenic mutations in BRAF are common in melanoma and drive constitutive activation of the MEK/ERK ...
Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon...